
Genmab Gains, Sabadell Rises, Vend Tumbles
Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:
- Genmab and AbbVie’s epcoritamab & R-CHOP combination for Diffuse large B-cell lymphoma cut the risk of disease progression or death by 51%, according to phase 3 topline data. Analysts say the positive results help de-risk sales expectations, with progression-free survival rate ahead of expected bar.
- BPCE acquired a stake of about 7% in Spain’s Banco Sabadell SA as Chief Executive Officer Nicolas Namias seeks to expand business outside the French home market.
- Vend Marketplaces shares fall…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.